Feasibility, accuracy, and safety of 3-dimensional ⁴₅⁴ electroanatomic mapping without fluoroscopy in patients with congenital heart defects

Apinya Bharmanee, MD,^{*} Srinath Gowda, MD,[†] Harinder R. Singh, MD, FHRS, CEPS, CCDS[†]

From the ^{*}Division of Pediatric Cardiology, The Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan, and [†]Division of Cardiology, Department of Pediatrics, Children's Hospital of San Antonio, Baylor College of Medicine, San Antonio, Texas.

15 BACKGROUND Use of nonfluoroscopic 3-dimensional electroana-16 tomic mapping (NF-3DEAM) in patients with congenital heart defects (CHDs) is not well reported. 17

18 OBJECTIVE The purpose of this study was to evaluate the 19 feasibility, accuracy, and safety of NF-3DEAM in patients with CHDs. 20

METHODS Retrospective review of electrophysiologic study (EPS) 21 in patients with CHD from 2009 to 2013 was conducted. Patients 22 undergoing EPS with NF-3DEAM using the EnSite NavX system (St. 23 Jude Medical) were included and those with fluoroscopy were 24 excluded. Cardiac angiography performed in close proximity was 25 matched with 3DEAM by proper aspect ratio using manual align-26 ment by overlay images and comparing distances between cardiac 27 landmarks using Pearson correlation coefficient and intraclass 28 correlation. Success and complications were reviewed.

29 **RESULTS** Three-dimensional electroanatomic mapping and angio-30 grams were compared in 48 EPS (45 patients); 13 patients with 31 intracardiac leads, guiescent chambers indicating significant scar-32 ring, and who required transseptal puncture were excluded. 33

35 Introduction

36 Advances in 3-dimensional electroanatomic mapping 37 (3DEAM) have reduced radiation exposure during electro-38 physiologic study (EPS) in addition to the main utilities, 39 including activation mapping, voltage mapping, catheter 40 position, and ablation for defining lesions. The principle of 41 3DEAM involves generating a magnetic field, creating a 42 virtual 3-dimensional image, and recording voltage and 43 impedance using a mapping and reference catheter. Three-44 dimensional electroanatomic mapping is traditionally per-45 formed with fluoroscopic guidance and has been used for 46 pediatric supraventricular tachycardia mapping and ablation 47 with documented success without compromise in results or 48 safety.¹⁻⁶ Previous studies also reported successful reduction 49 or elimination of fluoroscopy in pediatric patients with 50

51

34

1 2 3

6 7

8

10

11

12

13 14

- 52 Address reprint requests and correspondence: Dr. Harinder R Singh, 315 53
- N San Saba St, Suite 1135, San Antonio, TX 78207. E-mail address:
- 54 Harinder.singh@christushealth.org.

Indications for EPS included documented tachyarrhythmia and preoperative mapping. Mean age was 25.3 ± 9.8 years. Simple CHDs (isolated shunt lesions or valvular lesions) were identified in 13 studies (27%) and complex CHDs (others) were identified in 35 studies (73%). Ablations were performed in 25 studies (52%). Average time to obtain right atrial geometry was 25.3 minutes (range 14-47 minutes) and right ventricular geometry was 22.8 minutes (range 12-35 minutes). Pearson correlation coefficient and intraclass correlation of cardiac landmarks were 0.90 and 0.80, respectively. Anatomic landmarks, mapping, and ablation were accurate in all 3DEAMs. No complications were recorded.

CONCLUSION NF-3DEAM is feasible, safe, and accurate in CHD patients without extensive scarring, intracardiac leads, and need for transseptal puncture.

KEYWORDS Three-dimensional electroanatomic mapping; Congenital heart defect; Feasibility; Safety; accuracy

(Heart Rhythm 2016;0:0-7) © 2016 Heart Rhythm Society. All rights reserved.

normal cardiac anatomy.^{3,5-7} A few case reports on the success of 3DEAM in patients with congenital heart defects (CHDs) have been reported.⁸⁻¹⁰ To date, no studies on the utility of nonfluoroscopic 3DEAM (NF-3DEAM) in CHD patients have been conducted. The purpose of this study was to evaluate the accuracy, feasibility, and safety of NF-3DEAM in the CHD population.

Methods

Study design and patient selection

A retrospective single institutional review of patients with repaired and unrepaired CHDs who underwent EPS using NF-3DEAM from July 2009 to July 2013 for mapping and ablation was performed. The study was approved by the Institutional Review Board. Only patients who had undergone angiography for hemodynamic or interventional cardiac catheterization within 9 months of EPS were selected to aid in comparing accuracy. No patient underwent angiography to help with navigation of 3DEAM. Patients with

73

74

75

2

76 hemodynamically insignificant valvular heart disease, such 77 as bicuspid aortic valve without aortic insufficiency, mitral 78 valve prolapse, and patent ductus arteriosus, were excluded. 79 CHD patients who underwent fluoroscopy by the transseptal 80 approach only were also excluded from our review. Demo-81 graphic data including age, weight, and height, type of 82 congenital heart lesions, indication for EPS, tachycardia 83 mechanism, and follow-up status were reviewed. EPS details 84 included time taken to obtain right atrial (RA) and right 85 ventricular (RV) geometries (if performed), complications 86 that occurred during or immediately after the procedure, and 87 success rates. 88

⁸⁹ Three-dimensional electroanatomic mapping

90 Three-dimensional electroanatomic mapping was performed 91 using the EnSite NavX system (St. Jude Medical, St. Paul, 92 MN). EP-Workmate (St. Jude Medical) was used for 93 stimulation and recording in all cases. Cardiac magnetic 94 resonance imaging, computed tomography, and intracardiac 95 echocardiography were not used during EPS. All EPS was 96 performed under general anesthesia by 1 pediatric electro-97 physiologist experienced in routinely performing EPS using 98 NF-3DEAM. Femoral venous access was the preferred route. 99 The EnSite NavX surface electrodes were placed per 100 protocol but were trimmed for smaller patients per the 101 F1 manufacturer's recommendations (Figure 1). Venous anat-102 omy was obtained as a steerable catheter was advanced from 103 the venous access site. RA geometry was created from the 104 point of obtaining the first atrial electrogram and marked as 105 the inferior vena cava (IVC)-RA junction. The catheter was 106 then guided into the superior vena cava (SVC), and the point 107 of the SVC-RA junction where the atrial electrogram 108 disappeared was located. The catheter was then maneuvered 109 into the rest of the RA, the valvular points were marked, the 110 location of His potentials was marked, and the catheter was 111 positioned in the coronary sinus (CS) (when feasible). The 112 tricuspid annular points where the atrial and ventricular 113 electrogram signals were equal were marked. RV geometry 114 was obtained in patients who underwent ventricular 115

Heart Rhythm, Vol 0, No 0, Month 2016

tachycardia (VT) study. A similar method was used to obtain 133 RV geometry. From the tricuspid annular point, the steerable 134 catheter was gently advanced to the RV apex and maneu-135 vered in the RV cavity with constant rhythm monitoring. The 136 pulmonary annular point was located when the ventricular 137 signals disappeared. In contrast to RA geometry, RV 138 geometry usually was obtained to identify important land-139 marks and sites having potential as the arrhythmia substrate, 140 rather than for complete geometry. In patients with unique 141 anatomy, lesion-specific landmarks were used. In patients 142 with an RV-to-pulmonary artery conduit, the base or 143 proximal part of the conduit landmark was defined. For 144 patients with D-transposition of the great arteries who had 145 undergone an atrial switch operation, the SVC, superior 146 mitral annulus, and left atrial appendage tip were used. 147 Voltage mapping was performed simultaneously to map scar 148 tissue in all CHD patients. EPS was performed using 149 standard protocols, with catheters placed in the high RA, 150 across the tricuspid valve into the RV septum for monitoring 151 His-bundle signals, in the CS (if feasible), in the RV apex, 152 and in the RV outflow tract. 153

Angiography and fluoroscopy from recent cardiac catheterizations

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

Biplane angiographic images and fluoroscopy obtained from recent cardiac catheterizations, performed for either diagnostic or interventional purposes within 9 months, were used for correlation and comparison of the electroanatomic shell created. When more than one angiogram or fluoroscopy was available, the study closest to the date of EPS was chosen for comparison. In patients who underwent congenital heart surgery after EPS, only preoperative cardiac catheterization was selected for comparison. The angiographic and fluoroscopic images were reviewed by an interventional cardiologist. The measurements were performed online using the Syngo system (Siemens Healthcare, Germany), and the maximum dimension measured **Q** was used for comparison.




 Figure 1
 Ensite NavX surface electrodes. Trimmable portion is shaded. (Adapted from Ensite System Model EE3000, Version 8.0, Instructions for Use. U.S. Edition 54-06154-001, 2008, Chapter 3, p 40.)
 100

Download English Version:

https://daneshyari.com/en/article/5959059

Download Persian Version:

https://daneshyari.com/article/5959059

Daneshyari.com